Stocktoria
ALNYLAM PHARMACEUTICALS, INC. ALNY
ALNYLAM PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M | $492.9M | $219.8M | $74.9M | $89.9M | $47.2M |
| R&D expense | $1.3B | $1.1B | $1.0B | $883.0M | $792.2M | $654.8M | $655.1M | $505.4M | $390.6M | $382.4M |
| SG&A expense | $1.2B | $975.5M | $795.6M | $770.7M | $620.6M | $588.4M | $479.0M | $382.4M | $199.4M | $89.4M |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M | -$828.4M | -$939.4M | -$814.7M | -$500.1M | -$424.6M |
| Interest expense | — | — | $121.2M | $156.0M | $143.0M | $84.5M | $0 | $0 | — | — |
| Income tax | $9.4M | -$99.2M | $6.7M | $4.2M | $680,000 | $2.7M | $863,000 | $823,000 | $0 | $0 |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.1B | -$852.8M | -$858.3M | -$886.1M | -$761.5M | -$490.9M | -$410.1M |
| EPS (diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | — | — | — |
| Operating cash flow | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M | -$615.0M | -$278.4M | -$562.6M | -$382.8M | -$307.7M |
| Free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M | -$685.3M | -$418.6M | -$689.5M | -$487.0M | -$372.3M |
| Cash & equivalents | $1.7B | $966.4M | $812.7M | $866.4M | $820.0M | $496.6M | $547.2M | $420.1M | $645.4M | $193.6M |
| Inventory | $82.7M | $78.5M | $89.1M | $129.0M | $86.4M | $75.2M | $56.3M | $24.1M | — | — |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B | $3.4B | $2.4B | $1.6B | $2.0B | $1.3B |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B | $2.4B | $956.4M | $272.8M | $228.3M | $342.6M |
| Shareholders' equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M | $1.0B | $1.4B | $1.3B | $1.8B | $920.2M |
Growth · year-over-year · Revenue CAGR 62.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +65.2% | +23.0% | +76.2% | +22.9% | +71.3% | +124.3% | +193.4% | -16.7% | +90.7% | — |
| Free cash flow growth | — | -201.5% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.